# Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

> **NCT06601504** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hutchmed** · enrollment: 61 (actual)

## Conditions studied

- Relapsed/Refractory Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** HMPL-760 planned dose 1
- **DRUG:** R-GemOx
- **DRUG:** HMPL-760 placebo planned dose 1
- **DRUG:** HMPL-760 planned dose 2
- **DRUG:** HMPL-760 placebo planned dose 2

## Key facts

- **NCT ID:** NCT06601504
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-05
- **Primary completion:** 2026-05-12
- **Final completion:** 2026-11-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06601504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06601504, "Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06601504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*